Why the study?
SGLT2 inhibitors reduce blood pressure in patients with diabetes mellitus, prompting an evaluation of their antihypertensive mechanisms and clinical benefits in patients with diabetes and hypertension.
Do SGLT2 inhibitors reduce arterial blood pressure in patients with diabetes mellitus and arterial hypertension?
Do SGLT2 inhibitors reduce arterial blood pressure in patients with diabetes mellitus and arterial hypertension?
This review highlights the mechanisms and clinical benefits of SGLT2 inhibitors in providing mild but effective blood pressure reduction in patients with diabetes and hypertension.
May support SGLT2 inhibitor use in diabetic HF or CKD; leaves open confirmation in larger prospective trials.
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new class of medications used for the treatment of diabetes mellitus (DM). It has been shown that, in addition to a favorable metabolic effect, they significantly reduce atherosclerotic events, cardiovascular and total mortality, hospitalization duration in patients with heart failure and have a significant effect on reducing the progression of chronic kidney disease. It has been observed that in patients with diabetes mellitus, they lead to a reduction of blood pressure (BP). The aim of this article is to evaluate current knowledge about mechanisms of antihypertensive action and clinical benefits of SGLT2 inhibitors in reducing arterial blood pressure in patients with diabetes mellitus and arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Branislava Ivanović (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: